Eli Lilly (NYSE:LLY) reported landmark Phase 3 results for Retevmo as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 trial found an 83% reduction in ...
Source Link- Like
- Comment
- Favorite
Eli Lilly Retevmo Trial Success And Valuation Signal Potential Upside
Simply Wall St.06-02 17:16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet